Biomerica, Inc. (NASDAQ:BMRA – Get Free Report) was the target of a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 51,400 shares, adropof24.2% from the July 15th total of 67,800 shares. Based on an average daily trading volume, of 49,800 shares, the days-to-cover ratio is presently 1.0 days. Approximately2.2% of the shares of the company are sold short. Approximately2.2% of the shares of the company are sold short. Based on an average daily trading volume, of 49,800 shares, the days-to-cover ratio is presently 1.0 days.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Biomerica stock. Bulltick Wealth Management LLC purchased a new stake in Biomerica, Inc. (NASDAQ:BMRA – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 137,149 shares of the company’s stock, valued at approximately $78,000. Bulltick Wealth Management LLC owned 5.39% of Biomerica at the end of the most recent reporting period. 22.28% of the stock is owned by institutional investors.
Biomerica Trading Up 8.1%
NASDAQ:BMRA opened at $3.21 on Thursday. Biomerica has a 1 year low of $2.08 and a 1 year high of $10.16. The firm’s fifty day simple moving average is $3.27 and its 200 day simple moving average is $4.04. The firm has a market capitalization of $8.19 million, a PE ratio of -1.38 and a beta of 0.26.
About Biomerica
Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.
Read More
- Five stocks we like better than Biomerica
- What Do S&P 500 Stocks Tell Investors About the Market?
- Lowe’s Builds Value for Investors: Still a Good Buy in 2025
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Jackson Hole 2025: Fed’s Signal Could Shift Stocks Fast
- What Are the U.K. Market Holidays? How to Invest and Trade
- Rocket Lab Stock: Breakout Brewing or Time for Patience?
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.